Plasminogen Activator Inhibitors -Pipeline Insights, 2015 -- A DelveInsight Report

NEW DELHI - Aug. 6, 2015 - PRLog -- DelveInsight, the leading market research company has added new report “Plasminogen Activator Inhibitors -Pipeline Insights, 2015” to its portfolio. With this launch Delveinsight now has 700+ Reports on Mechanism of Action (MOA) Pipeline Insight. DelveInsight is the only company that promulgates Mechanism of Action (MOA) Pipeline Insight Reports. In addition to this our research expertise provides our clients with up to date information of market till the date of order.

The “Plasminogen Activator Inhibitors -Pipeline Insights, 2015” report will help companies to optimize their portfolio by analyzing the market and creating effective counter-strategies for collaborations and licensing deals. In addition to this report on “Plasminogen Activator Inhibitors -Pipeline Insights, 2015”comprehensively includes:

·   • Information on 10 pipeline drugs which includes 1 in Phase II , 4 in Preclinical ,3 discontinued and 2 inactive drugs along with 9 companies actively involved in drug development.

·    • D-Pharm Ltd involved in the development of THR-18. Drug is under Phase II clinical trial.

·    • Therapeutic targets and their mechanism of action (MOA) according to latest R&D, pipeline products, technologies, clinical profiling, molecule type and stages of development.

·     • Information on collaborations and in-licensing & out-licensing deals

DelveInsight is offering the Report at a price of USD 1250 as a single user license, USD 2500 as a site license and USD 4000 as a Global/Enterprise License.

About
DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making;identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Website: http://delveinsight.com